|LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information|
LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat
hypotrichosis of the eyelashes by increasing their growth, including length,
thickness, and darkness.
Important Safety Information
Warnings and Precautions: In patients using LUMIGAN®(bimatoprost ophthalmic
solution) or other prostaglandin analogs for the treatment of elevated intraocular
pressure (IOP), the concomitant use of LATISSE®may interfere with the desired
reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for
IOP reduction should only use LATISSE® after consulting with their physician and
should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was
administered. Patients should be advised about the potential for increased brown
iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to
periorbital pigmented tissues and eyelashes. The pigmentation is expected to
increase as long as bimatoprost is administered, but has been reported to be
reversible upon discontinuation of bimatoprost in most patients.
There is the potential for hair growth to occur in areas where LATISSE®solution
comes in repeated contact with skin surfaces. Apply LATISSE®only to the skin of
the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular
inflammation (eg, uveitis) because the inflammation may be exacerbated.
Adverse Reactions: The most frequently reported adverse events were eye
pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye
symptoms, and erythema of the eyelid. These events occurred in less than 4% of
Postmarketing Experience: The following reactions have been identified during
postmarketing use of LATISSE® in clinical practice: burning sensation (eyelid),
erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus,
iris hyperpigmentation, lacrimation increased, madarosis and trichorrhexis
(temporary loss of a few eyelashes to loss of sections of eyelashes, and
temporary eyelash breakage, respectively), rash (including macular,
erythematous, and pruritic limited to the eyelids and periorbital region), skin
discoloration (periorbital), and vision blurred.
Use in Specific Populations: Use in pediatric patients below the age of 16 years
is not recommended because of potential safety concerns related to increased
pigmentation following long-term chronic use.
Please see the full Prescribing Information.